宫颈癌肿瘤微环境中程序性死亡配体1与分化簇163表达的动态变化:单中心回顾性研究
该单中心回顾性研究纳入26例完成根治性放疗的宫颈癌患者,按治疗开始后2年内是否复发和/或转移分为治疗失败组(n=14)和治疗成功组(n=12),评估治疗期间肿瘤微环境中程序性死亡配体1(PD-L1)、分化簇163(CD163)等标志物的表达变化。结果显示,近距离治疗中点时治疗成功组PD-L1和CD163表达水平低于治疗失败组(p<0.01和p=0.08),2年无进展生存(PFS)率取决于PD-L1和CD163表达水平(p=0.04和p=0.02)。作者认为近距离治疗期间肿瘤微环境中CD163和PD-L1表达率与治疗反应及2年PFS相关。
要点
- 近距离治疗中点时治疗成功组PD-L1表达低于治疗失败组(p<0.01),CD163表达低于治疗失败组(p=0.08)。
- 2年PFS率取决于PD-L1表达水平(p=0.04)和CD163表达水平(p=0.02)。
- 近距离治疗期间肿瘤微环境中CD163和PD-L1表达率与治疗反应及2年PFS相关。
核心结论
- 近距离治疗期间肿瘤微环境中CD163和PD-L1的表达率与治疗反应及2年PFS相关。
- 本研究可能增进对肿瘤微环境中肿瘤相关免疫的理解,并有助于开发针对PD-L1或M2巨噬细胞的疗法联合放疗(尤其是近距离治疗)用于宫颈癌患者。
研究设计与样本
- 单中心回顾性研究,纳入26例完成根治性放疗(外照射联合近距离治疗)的宫颈癌患者。
- 按治疗开始后2年内是否复发和/或转移分为治疗失败组(n=14)和治疗成功组(n=12)。
- 在治疗期间定期采集宫颈组织,评估肿瘤微环境中PD-1、PD-L1、CD8、CD68、CD163、FOXP3和HIF-1α的表达。
主要发现
- 近距离治疗中点时,治疗成功组肿瘤微环境中PD-L1表达水平低于治疗失败组(p<0.01)。
- 近距离治疗中点时,治疗成功组肿瘤微环境中CD163表达水平低于治疗失败组(p=0.08)。
- 2年PFS率取决于PD-L1表达水平(p=0.04)和CD163表达水平(p=0.02)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Radiotherapy (RT) destroys cancer cells and activates the immune system while suppressing the immunity of tumor-associated tissues, including the tumor microenvironment (TME). However, to date, no anti-tumor therapeutic strategy that uses these immune mechanisms has been established. This study investigated changes in the immunity of the TME during standard radical RT for cervical cancer combined with external beam RT and brachytherapy and determined whether these changes affect prognosis. METHODS: Twenty-six patients who had completed radical RT for cervical cancer were categorized into the following two groups according to whether the cancer recurred and/or metastasized within 2 years after the start of treatment: treatment failure (n = 14) and treatment success (n = 12). We assessed the expression of programmed death 1, programmed death ligand 1 (PD-L1), cluster of differentiation (CD) 8, CD68, CD163, Forkhead box protein P3, and hypoxia-inducible factor-1α in the TME of cervical tissues collected periodically during treatment and evaluated the difference in expression rates of each marker between the success and failure groups and assessed its effect on prognosis. RESULTS: The expression levels of PD-L1 and CD163 in the TME in the treatment success group were lower than those in the treatment failure group at the midpoint during brachytherapy (p < 0.01 and p = 0.08, respectively), and the 2-year progression-free-survival (PFS) rate depended on the expression levels of PD-L1 and CD163 (p = 0.04 and p = 0.02, respectively). CONCLUSIONS: The expression rates of CD163 and PD-L1 in the TME during brachytherapy were related to treatment response and the 2-year PFS. This study may increase our understanding of tumor-associated immunity in the TME and aid in the development of therapies targeting PD-L1 or M2 macrophages in the TME in conjunction with RT, especially brachytherapy, for cervical cancer patients.
引用
- Miyata Y, Ogo E, Abe T, et al. Dynamics in the expression of programmed death ligand 1 and cluster of differentiation 163 in the tumor microenvironment of uterine cervical cancer: a single-center retrospective study. Radiat Oncol. 2023. PMID: 36823665. doi:10.1186/s13014-023-02230-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。